伐尼克兰、安非他酮与尼古丁贴片在吸烟者中的心血管安全性:一项随机临床试验
EAGLES是一项双盲、随机、三模拟、安慰剂和活性对照试验,在140个跨国中心纳入至少接受1剂研究药物的吸烟者8058例(有或无既定精神科诊断),并对其完成12周治疗加12周随访后同意再随访28周的4595例亚组进行分析。干预为伐尼克兰1 mg每日两次、安非他酮盐酸盐150 mg每日两次、尼古丁替代疗法21 mg/d贴片并逐渐减量。主要终点为治疗期间发生主要不良心血管事件(MACE:心血管死亡、非致死性心肌梗死或非致死性卒中)的时间;治疗和随访期间心血管事件发生率低(MACE<0.5%;MACE+<0.8%),各治疗组间无显著差异。伐尼克兰与安慰剂相比MACE发生时间的风险比为0.29(95%CI 0.05-1.68),安非他酮为0.50(95%CI 0.10-2.50),均无显著差异。结论认为未观察到戒烟药物增加严重心血管不良事件风险的证据。
要点
- 在8058例吸烟者中,治疗和随访期间MACE发生率<0.5%,MACE+发生率<0.8%,各治疗组间无显著差异。
- 伐尼克兰 vs 安慰剂MACE发生时间HR 0.29(95%CI 0.05-1.68),安非他酮 vs 安慰剂HR 0.50(95%CI 0.10-2.50),均无显著差异。
- 各治疗组间血压和心率也无显著差异。
- 结论:未观察到戒烟药物增加严重心血管不良事件风险的证据。
适用人群与场景
- 吸烟者,有或无既定精神科诊断,至少接受1剂研究药物(n=8058)。
- 完成12周治疗加12周随访并同意再随访28周的亚组(n=4595)。
处置流程与药物剂量
- 伐尼克兰1 mg每日两次。
- 安非他酮盐酸盐150 mg每日两次。
- 尼古丁替代疗法21 mg/d贴片并逐渐减量。
研究设计与关键结果
- 双盲、随机、三模拟、安慰剂和活性对照试验(EAGLES)及其非治疗扩展试验,在140个跨国中心进行,纳入至少接受1剂研究药物的吸烟者8058例(44.1%为男性,平均年龄46.5岁[SD 12.3]),以及完成12周治疗加12周随访并同意再随访28周的亚组4595例。
- 主要终点为治疗期间发生MACE(心血管死亡、非致死性心肌梗死或非致死性卒中)的时间;治疗和随访期间MACE发生率<0.5%,MACE+发生率<0.8%,各治疗组间无显著差异。
- 伐尼克兰 vs 安慰剂MACE发生时间HR 0.29(95%CI 0.05-1.68);安非他酮 vs 安慰剂HR 0.50(95%CI 0.10-2.50),均无显著差异。
- 各治疗组间血压和心率无显著差异。
证据类型、等级与局限
- 证据类型:随机对照试验(双盲、随机、三模拟、安慰剂和活性对照试验)及其非治疗扩展试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论:未观察到戒烟药物增加严重心血管不良事件风险的证据;EAGLES及其扩展试验提供进一步证据表明戒烟药物不增加普通吸烟者人群严重心血管事件风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Quitting smoking is enhanced by the use of pharmacotherapies, but concerns have been raised regarding the cardiovascular safety of such medications.
OBJECTIVE: To compare the relative cardiovascular safety risk of smoking cessation treatments.
DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, triple-dummy, placebo- and active-controlled trial (Evaluating Adverse Events in a Global Smoking Cessation Study [EAGLES]) and its nontreatment extension trial was conducted at 140 multinational centers. Smokers, with or without established psychiatric diagnoses, who received at least 1 dose of study medication (n = 8058), as well as a subset of those who completed 12 weeks of treatment plus 12 weeks of follow up and agreed to be followed up for an additional 28 weeks (n = 4595), were included.
INTERVENTIONS: Varenicline, 1 mg twice daily; bupropion hydrochloride, 150 mg twice daily; and nicotine replacement therapy, 21-mg/d patch with tapering.
MAIN OUTCOMES AND MEASURES: The primary end point was the time to development of a major adverse cardiovascular event (MACE: cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) during treatment; secondary end points were the occurrence of MACE and other pertinent cardiovascular events (MACE+: MACE or new-onset or worsening peripheral vascular disease requiring intervention, coronary revascularization, or hospitalization for unstable angina).
RESULTS: Of the 8058 participants, 3553 (44.1%) were male (mean [SD] age, 46.5 [12.3] years). The incidence of cardiovascular events during treatment and follow-up was low (<0.5% for MACE; <0.8% for MACE+) and did not differ significantly by treatment. No significant treatment differences were observed in time to cardiovascular events, blood pressure, or heart rate. There was no significant difference in time to onset of MACE for either varenicline or bupropion treatment vs placebo (varenicline: hazard ratio, 0.29; 95% CI, 0.05-1.68 and bupropion: hazard ratio, 0.50; 95% CI, 0.10-2.50).
CONCLUSIONS AND RELEVANCE: No evidence that the use of smoking cessation pharmacotherapies increased the risk of serious cardiovascular adverse events during or after treatment was observed. The findings of EAGLES and its extension trial provide further evidence that smoking cessation medications do not increase the risk of serious cardiovascular events in the general population of smokers.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01574703.
参考来源
- Benowitz NL, Pipe A, West R, et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med. 2018. PMID: 29630702. doi:10.1001/jamainternmed.2018.0397
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。